1. Home
  2. EDUC vs NCEL Comparison

EDUC vs NCEL Comparison

Compare EDUC & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Educational Development Corporation

EDUC

Educational Development Corporation

HOLD

Current Price

$1.32

Market Cap

11.8M

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$2.85

Market Cap

13.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EDUC
NCEL
Founded
1965
2008
Country
United States
Switzerland
Employees
N/A
11
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
13.2M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
EDUC
NCEL
Price
$1.32
$2.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
23.1K
23.1K
Earning Date
04-14-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.63
N/A
Revenue
$34,191,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.13
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$1.89
52 Week High
$1.84
$4.70

Technical Indicators

Market Signals
Indicator
EDUC
NCEL
Relative Strength Index (RSI) 40.26 55.26
Support Level $1.32 $2.44
Resistance Level $1.36 $3.19
Average True Range (ATR) 0.06 0.11
MACD -0.01 0.01
Stochastic Oscillator 25.00 68.57

Price Performance

Historical Comparison
EDUC
NCEL

About EDUC Educational Development Corporation

Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.

Share on Social Networks: